Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PRSO Ladenburg analyst Jon Hickman initiated coverage of Peraso with a Buy rating and $3.75 price target.
https://www.tipranks.com/news/the-fly/peraso-initiated-with-a-buy-at-ladenburg?mod=mw_quote_news
$HNRC May 15th News Story Houston Natural Resources reports Q1 results
https://seekingalpha.com/news/4106860-houston-natural-resources-reports-q1-results?utm_source=otcmarkets&utm_medium=referral&feed_item_type=news
$MMA - Alta Global Group Ltd (NYSEAMERICAN: MMA) stock could see a quick bounce anytime. The stock has been falling on a very low volume – signaling weak hands are almost out. Smart people must be still holding for the company’s growth. Now at $2.64, with a solid support at $2.4-2.50, it has potential to fill the gap to $3.70-3.80.
$BDCC - announces they have secured the services of Mohammed Rahmatullah as a strategic consultant. Mohammed is expected to play a pivotal role in all negotiations involving the printing of 3D homes.
https://finance.yahoo.com/news/blackwell-3d-corporation-secures-services-040533630.html
$INBS Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector
https://www.globenewswire.com/news-release/2024/06/20/2901687/0/en/Intelligent-Bio-Solutions-Broadens-UK-Customer-Base-by-Securing-Two-Key-Accounts-with-Over-70-Locations-and-Over-15-000-Employees-in-the-Warehouse-and-Logistics-Sector.html
$MMA stock has been falling on a very low volume. It’s a matter of time, the stock forms the bottom at around $2.50 (Major support), and starts moving higher.
Noticeably, Alta Global Group (NYSE American:MMA) has partnered with Australian former UFC fighter Jessica-Rose Clark – this would strengthen its connection with the global MMA community, encouraging fans to actively participate in martial arts.
$AGBA reports that on May 16, 2024, Triller Corp delivered to its stockholders a notice pursuant to Section 228(e) of the Delaware General Corporation Law, laying out specific details of the proposed merger between Triller and AGBA.
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore
$PRSO Peraso Inc Director Ian Mcwalter bought 100,000 shares of Peraso stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average cost of $1.27 per share, with a total value of $127,000.00. Following the acquisition, the director now owns 101,246 shares of the company’s stock, valued at $128,582.42. The transaction was disclosed in a document filed with the SEC, which is available
https://www.sec.gov/Archives/edgar/data/890394/000121390024052243/xslF345X05/ownership.xml
$FAVO News January 30, 2024
FAVO Capital, Inc Welcomes Glen Steward as Chief Strategy Officer
https://finance.yahoo.com/news/favo-capital-inc-welcomes-glen-142000952.html
$DTII Defense Technologies International Corp. (DTII) Appoints Head of West Coast Marketing
https://www.newsfilecorp.com/release/212778/Defense-Technologies-International-Corp.-DTII-Appoints-Head-of-West-Coast-Marketing?utm_source=dlvr.it&utm_medium=twitter
$FAVO - The decision to engage Turner Stone underscores FAVO Capital's commitment to maintaining the highest standards of financial integrity and transparency. FAVO Capital aims to enhance its financial reporting processes and ensure continued PCAOB compliance within the industry.
https://finance.yahoo.com/news/favo-capital-inc-appoints-turner-171500774.html
$CATV: Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector
MIAMI, May 15, 2024 /PRNewswire/ -- 4Cable TV International, Inc. soon to be known as Category V Biotech, Inc. (OTC: CATV) announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC (https://geneticnetworks.com/), a leader in applied molecular biology and drug development. Effective May 15, 2024, the LOI signifies Category V Biotech's acquisition of 100% equity interests in Genetic Networks, marking the company's entry into the biotechnology sector of the Cannabis industry and solidifying its position as a fully integrated global leader in this space.
Genetic Networks brings a proprietary platform known as GeneScape™, which facilitates the rapid and unbiased discovery of optimal drug compounds through whole-genome analysis. By integrating functional assays of drug activity and human gene variants, GeneScape™ can identify the most promising targets and compounds for specific diseases, expediting development timelines and reducing costs. This acquisition enables Category V Biotech to expand into the biotech aspect of the Cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.
"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of Cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before as regulated FDA products under the new regulatory environment of the United States."
Under the agreement's terms, Category V Biotech will acquire 100% of Genetic Networks. The transaction is expected to conclude in the second quarter of 2024, pending customary closing conditions.
Dr. Gennaro D'Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."
Following the acquisition, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global Cannabis operations, including cultivation, biotech research, and retail.
This transaction is the culmination of years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using Cannabis. With the recent announcement of the rescheduling of Cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, the long-awaited strategy can now come to fruition. This shift paves the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the Cannabis industry, driving innovation and advancing therapeutic solutions for patients.
Category V Biotech remains actively engaged in pursuing additional acquisitions in the Cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.
About Genetic Networks, LLC
Genetic Networks, LLC, established in 2015, has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis.
About Category V Biotech, LLC, Inc.
Category V Biotech, LLC, Inc. (OTC: CATV) aims to establish and operate a fully integrated global Cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical Cannabis- based products and therapies.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements regarding Category V Biotech, LLC's business, which are not historical facts but are based on the company's current beliefs, expectations, and assumptions about its future business, plans, strategies, projections, anticipated events, and trends. Such forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are beyond the company's control. Actual results and financial conditions may differ materially from those indicated in the forward- looking statements due to various factors. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, made from time to time, except as required by law.
SOURCE: 4Cable TV International, Inc a/k/a Category V Biotech, LLC, Inc. (OTC: CATV)
Contact: info@4cabletvint.com, +1 3055289614
Cision View original content:https://www.prnewswire.com/news-releases/category-v-biotech-inc-announces-letter-of-intent-to-acquire-genetic-networks-expanding-into-biotechnology-sector-302146392.html
SOURCE 4Cable TV International, Inc.
CRDL – I am very excited about the upcoming outcome from the FDA on the company’s Ph2 Pericarditis data release. I have been holding since $2.30 and once we get the green signal, we could easily see 5+++.
Remember, multiple analysts are anticipating strong outcome and set a bullish PT of $8-9. I hope I can sell half of holdings at least at $7-8.
$BLGO BioLargo Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-ion
https://finance.yahoo.com/news/biolargo-manufactures-first-cellinity-battery-123000579.html
$CRDL resumes another round of breakout rally. It hits another multi-year high on Monday. Now all eyes are on the Ph2 Pericarditis data release (which may be this week or next). Considering the recent price movement, it looks like big guys have taken a major position in anticipation of a positive outcome. So one must keep $CRDL on the watchlist. Any positive outcome could trigger a huge rally.
$AGBA - Triller now fully focuses on pooling its resources and attention towards completing the proposed merger with AGBA within a short timetable.
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore
$CRDL looks interesting here and may bounce back anytime. The stock is already up 173% YTD and pulled back about 10% from multi-year high on a very low volume. Analysts have released bullish commentary on the stock as high as $9 PT.
Last week, Canaccord Genuity lifted the PT to $8 from $6 on Cardiol Therapeutics Inc (NASDAQ: CRDL) – Potential gain of 230% from CMP.
H.C. Wainwright & Co has a PT of $9.
$CBDW 1606 Corp. to Host Exclusive Live Investor Webinar and Q&A Session on June 11th
https://www.accesswire.com/871971/1606-corp-to-host-exclusive-live-investor-webinar-and-qa-session-on-june-11th
$RJDG RJD Green Inc.'s Silex Holdings Division Has Record Breaking Revenue in May
https://www.newmediawire.com/news/rjd-green-inc-s-silex-holdings-division-has-record-breaking-revenue-in-may-7075516
$OCX Last week, Oncocyte announced positive data results for its flagship diagnostic product, VitaGraft™.
In a phase 2 double-blind, placebo-controlled study (NCT05021484), VitaGraft Kidney was used to monitor graft injury associated with the investigational drug felzartamab, a fully human CD38 monoclonal antibody, aimed at treating antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.
VitaGraft Kidney assesses the health of grafts by measuring the amount of donor-derived DNA in the blood of transplant patients, serving as a crucial biomarker.
$MMA - Alta Global Group (NYSE American:MMA) announces significant partnership with legendary MMA coach Eric Nicksick, renowned for guiding three fighters to UFC championships, including Francis Ngannou, Aljamain Sterling, and Sean Strickland.
This big announcement is set to deepen Alta's connection with MMA's 640 million fans and convert fandom into active participation.
Alta estimates each active gym partnership could produce an average of $88,000 in annual revenue for the Company if they run two Alta Programs each year (average 24 participants per program) and cross-sell the Alta Pass, Academy products and Hype, Alta's all-in-one digital marketing platform for small business.
Alta has over 500 active gym partnerships and is targeting approximately 45,000 potential combat sports gym partners in the US as it expands its network globally.
$MMA Based on the technical chart, the risk-reward ratio is surely in buyers favor. The stock has been consolidating near $4, and it’s just a matter of time, we could see it flying above $5. Just need some patience!!
$CBDW 06/06 NEWS Redchip CEO interview CBDW.AI
$CRDL – Get ready for the biggest catalyst soon. The company may release FDA decision for Pericarditis Ph2 trial! It may hit the market next week.
Considering the rise of 180% this year, the stock looks good and if we get positive outcome, the stock may be ready to fly big. Analysts are already very bullish on the stock with PT of $8. So biotech traders must keep $CRDL on their radar.
$RWGI is proud to announce a significant strategic move including signing a Letter of Intent (LOI) for the dispensary's license acquisition, further solidifying RWGI's presence in the burgeoning cannabis market. https://finance.yahoo.com/news/rodedawg-otc-rwgi-expands-dispensary-120000919.html
$CBDW is pleased to invite investors to a webinar on June 11, 2024, at 4:15 p.m. ET. https://finance.yahoo.com/news/rodedawg-otc-rwgi-expands-dispensary-120000919.html
$FAVO - Geographical Reach: FAVO Capital is extending its footprint into new states and countries, providing a broader spectrum of clients with access to its innovative financial products and services.
https://finance.yahoo.com/news/favo-capital-inc-opens-second-131500325.html
#favocapital @favocap
$AGBA - The Merger represents a distinctive fusion of social media, content, fintech and healthtech, driven by the powerful AI capabilities of the Combined Group.
https://finance.yahoo.com/news/building-digital-economy-titan-agba-130000244.html
$CBDW GET IN EARLY!!! HUGE RUN IS COMING... https://schrts.co/hmwnqQen
$RWGI Announces Successful Launch of Nutrient CBD Product Line https://finance.yahoo.com/news/rodedawg-otc-rwgi-announces-successful-120000632.html
$AIMD NEWS
Ainos | AI + Nose $AIMD #NASDAQ ** NEWS**
— The Great Bull Run! (@chazzsheen3) June 5, 2024
Thrilled to partner with Nisshinbo Micro Devices and Inabata to co-develop #VOC sensing platform for broader industry adoption! 🤝 @NisshinboMicro $AIMD $AIMDW #AINOSE #GiveMeNosehttps://t.co/WhVVAhvqlK… pic.twitter.com/pG4NV3fDKg
$AIMD announced the initiation of a clinical study for a new potential VELDONA®-based drug for pet disease. https://finance.yahoo.com/news/ainos-initiate-clinical-study-potential-120000724.html
$CBDW -- There is a hidden gem in the AI sector that Savvy investors should pay attention to.
$FAVO News May 22, 2024
FAVO Capital & Stewards Investment Capital Win Prestigious Global Finance Award
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-130500781.html
$AGBA News May 06, 2024
Empowering Shareholders: AGBA's US$4b Merger with Triller Ushers in New Era of Value Creation
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html
$AURI Today the company is sharing the detailed buyback, share reductions and share retirement program.
https://finance.yahoo.com/news/auri-inc-share-buyback-program-123600893.html
$CRDL - Analysts Reaffirm Significant Upside Potential for Cardiol Therapeutics
Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) - The company is currently developing CardiolRx™ and CRD-38 therapies for heart diseases, including recurrent pericarditis, acute myocarditis, and heart failure.
The stock has the potential for further upside considering the fact that Cardiol will release topline data for its Phase 2 MAvERIC-Pilot clinical trial evaluating the efficacy of CardiolRx™ for the treatment of recurrent pericarditis sometime in early June, which, if positive, has the potential to send the stock higher.
Several analysts have reiterated that the stock has the potential for significant upside, further reaffirming Cardiol’s growth prospects.
For instance, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.
According to Gantoss, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has many things going in its favor right now heading into a critical Phase 2 trial readout in recurrent pericarditis in June that he believes will lead to a positive outcome.
“Clearly, a $160 million market cap does not do Cardiol justice. With positive data in Q2, the path to market becomes a slam dunk, and the stock should surge to the upside in response,” says Gantoss.
In addition, analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and issued a $9 price target, which implies that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from current levels.
Read full details here https://www.nasdaq.com/press-release/analysts-consensus-reaffirms-significant-upside-potential-for-cardiol-therapeutics
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression
Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior"
NRX-101 demonstrated a similar antidepressant effect (MADRS reduction ~50%) compared to lurasidone, the Standard of Care drug
NRX-101 demonstrated a 58% relative reduction in time to sustained remission from suicidality (P=.05) compared to lurasidone
NRX-101 demonstrated a 76% reduction in symptoms of akathisia (p=0.03), a side effect linked to suicide, compared to lurasidone
This represents the second trial of NRX-101 demonstrating reduction in suicidality and akathisia associated with NRX-101 compared to lurasidone
RADNOR, Pa., May 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical stage pharmaceutical company, today announced presentation of its Phase 2b/3 trial of NRX-101, entitled "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior" at the American Society of Clinical Psychopharmacology (ASCP) in Miami Beach, FL. The lead author is Prof. Andrew Nierenberg, Director, Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital and Professor of Psychiatry, Harvard Medical School.
"Presentation of these data at this highly respected conference is another important step toward bringing a life-saving product to patients in tremendous need," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "We believe that NRX-101 may offer a paradigm changing approach to treatment of Bipolar Depression, with a product highly effective in both treating depression and reducing suicidality and associated side effects. We will continue working to bring hope to life with life-saving medications."
The presentation will be held at 11:15 AM, Wednesday May 29, 2024.
W89 A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior
CONCLUSIONS of the Poster are:
NRX-101 and lurasidone both demonstrated > 50% response for treating bipolar depression with no difference seen on primary efficacy endpoint (MADRS)
A clinically meaningful difference was observed on both primary and secondary safety endpoints favoring NRX-101NRX-101 was associated with 58% relative reduction in time to sustained remission from suicidality as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) when stratified by sex, mood stabilizer use, antipsychotic use, lifetime suicide event (P=0.05).NRX-101 was associated with a relative 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size 0.37; P=0.03) on the Barnes Akathisia Rating Scale
Akathisia was seen in 2% of participants treated with NRX-101 vs. 11% treated with lurasidone.
NRX-101 showed superiority to lurasidone in akathisia starting at day 7 and continuing through day 42/ET.
No treatment-related serious adverse event was observed in either group. No safety issues were detected except for MedDRA General disorders: NRX-101 - 18.2% vs lurasidone - 0% (p=0.002).
Based on these findings, together with the earlier STABIL-B trial, the Company believes that NRX-101 has potential to become a standard of care drug for treating bipolar depression, an addressable population of 7 million patients in the US and many times that around the world.
This study represents the second trial conducted under FDA Good Clinical Practices guidelines to demonstrate large and meaningful advantages of NRX-101 vs lurasidone on akathisia and suicidality and clears the path for a registration trial of NRX-101 vs. placebo to treat bipolar depression together with earlier accelerated approval for those with akathisia. An additional academic trial conducted by Chen and co-workers similarly demonstrated a statistically-significant reduction in suicidality associated with D-cycloserine, the active ingredient in NRX-101, compared to various standard of care antidepressants.
To the Company's knowledge, this trial and its prior STABIL-B study represent the only clinical trials in which an oral antidepressant has been demonstrated to cause meaningful reductions in suicidality and akathisia. All currently approved antidepressant drugs carry FDA-mandated "black box" warnings on their labels indicating that they may increase the risk of suicide. Similarly, akathisia – a side effect in which patients are agitated and frequently experience involuntary movement – is a side effect that occurs in 10-15% of patients who take the lurasidone class of drugs and is closely linked to suicide. As shown in the clinical trial, those randomized to lurasidone experienced a substantial increase in akathisia from baseline, whereas those randomized to NRX-101 demonstrated a statistically-significant reduction in akathisia (see Figure).
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL24282&sd=2024-05-28 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-presents-landmark-trial-of-nrx-101-in-suicidal-bipolar-depression-at-the-american-society-of-clinical-psychopharmacology-annual-meeting-nrx-101-is-the-first-oral-antidepressant-demonstrated-to-re-302156419.html
SOURCE NRx Pharmaceuticals, Inc.
$BSEG Kimberly Kates, CEO - Big Screen Entertainment Group
An important message from Kimberley Kates is, “We have a new line up of projects to make of 28 films from Hallmark to Horror to Faith based. We’ve been optioning scripts from top Hollywood writers the last 2 years. Our current focus for our films is not only to entertain, but also to shed inspiration hope and light in a somewhat dim world. Much of our new IP’s, scripts are about love, light and laughter. Our current slate of projects have that Spielberg touch: Heart, that Hollywood’s been missing for a while now.”
https://richardacavalli.wixsite.com/greenplanetmicrocaps/3-cent-entertainment-star-stock
News Company takeover!
$STGZ
We are thrilled to finally be able to share the news and excited for what's to come!https://t.co/IxIkE4tHMN
— Stargaze Entertainment Group, Inc. (@stargazegroup) May 24, 2024
Canaccord Genuity - PT Raised By 33% to $8 – Potential 260% rise
$CRDL – More reason to like the stock. Analyst at Canaccord Genuity lifted the PT to $8 from $6 – Potential gain of 260% from CMP
Big Catalyst - Cardiol is conducting an additional open-label Phase II MAvERIC-Pilot study for CardiolRx in recurrent pericarditis. The study is expected to report 8-week top-line data in Early June.
The report Further Says - We have incorporated a $75M equity raise in 3Q24 based on a positive outcome from the recurrent pericarditis Phase II trial. We extended the out-year of our model from a previous 2028 to 2035. We additionally have reduced the EU WAC pricing to 45% of U.S. pricing which is in-line with the current WAC pricing of epidiolex (comparator by mechanism, not indication).
$AVRW: Avenir Wellness / Sera Labs Inc. Partnership with Nicole Kidman - FabFitFun and Influencer Endorsements Drive Sales Growth for Seratoptical Revolutions Skin : Avenir Wellness Solutions, Inc. (Stock Symbol: AVRW)
https://www.einpresswire.com/article/711238053/solid-growth-for-seratoptical-revolutions-skin-care-line-boost-from-famed-fabfitfun-many-key-celebrities-otc-avrw
In this article:
Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
Company Currently Holds 15 Patents.
Seratopical Revolution Skin Care is Personally Used and Endorsed by Global Brand Ambassador & Strategic Partner Nicole Kidman and Other Major Celebrities.
LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting All Seratopical Revolution Plant-Based Products, Backed by Science with New “Ask the Expert” Videos, Answering Questions Directly from Customers.
Net Revenue in Q4 of 2023 Increased to $1.1 Million or 11.7%, Also Increased Sequentially from Q3 2023 by $43 Thousand, or 4.4%.
Sales Benefits Commencing From New Relationship with Leading Online and Beauty Subscription Box Retailer, FabFitFun.
$BMTM Are Digital Advertising Stocks A Safe Haven? Analyzing Alphabet, Bright Mountain Media and Key Players
https://techbullion.com/are-digital-advertising-stocks-a-safe-haven-analyzing-alphabet-bright-mountain-media-and-key-players/
$LVVV Livewire announced Financial Results for the First Quarter 2024
https://stockwatchindex.com/livewire-announced-financial-results-for-the-first-quarter-2024/
$CBDW 1606 Corp. Reports Great Success on IR Chat Sales Push and Shows Increased Revenue Last Quarter
https://finance.yahoo.com/news/1606-corp-reports-great-success-120000601.html
$AGBA - Since going public via a SPAC in November 2023, AGBA's team of over 1,500+ employees has worked tirelessly everyday in delivering steady growth persistently quarter after quarter maintaining our market leadership.
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html
$DYAI Dyadic International, Inc.’s (NASDAQ: DYAI) COO Joe Hazelton Discusses Expansion into Food and Beverage and the “Future Of Foods” on “The Street Reports Podcast” Listen Now!
https://thestreetreports.com/dyadic-international-inc-s-nasdaq-dyai-coo-joe-hazelton-discusses-expansion-into-food-and-beverage-and-the-future-of-foods-on-the-street-reports-podcast-listen-now/
$CBDW HUGE BUY ALERT!!! https://schrts.co/CEHzNJtQ
$HNRC REPORTS Q1 2024 FINANCIALS PERIOD ENDING MARCH 31, 2024
https://finance.yahoo.com/news/hnrc-reports-q1-2024-financials-120000780.html
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
RADNOR, Pa., May 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City.
Prof. Jonathan Javitt, MD, MPH, the Company's Chairman and Chief Scientist, and Matthew Duffy, the Company's Chief Business Officer, will hold one-on-one meetings with investors throughout the day. Interested parties can register to attend here.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
https://c212.net/c/img/favicon.png?sn=CL08030&sd=2024-05-08 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-to-participate-in-the-ef-hutton-annual-global-conference-on-may-15-2024-302139427.html
SOURCE NRx Pharmaceuticals, Inc.
$AGBA News May 06, 2024
Empowering Shareholders: AGBA's US$4b Merger with Triller Ushers in New Era of Value Creation
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |